Springboard Health Angels

Springboard Health Angels operates as a prominent Berlin-based investment collective specializing in early-stage life sciences ventures. Founded by experienced healthcare professionals and industry veterans, this angel group has established itself as a key funding source for innovative startups at the intersection of healthcare and technology. Their investment approach combines financial support with strategic mentorship, leveraging the diverse expertise of their membership to help portfolio companies navigate the complex healthcare landscape. Since their inception, they have built a reputation for identifying promising scientific breakthroughs with significant commercial potential.

The group maintains a dedicated focus on health technology innovations, including digital therapeutics, medical devices, diagnostic platforms, and AI-driven healthcare solutions. Their investment thesis centers on technologies that address significant unmet medical needs, improve patient outcomes, or substantially reduce healthcare delivery costs. Typically investing in pre-seed and seed rounds, Springboard provides capital infusions ranging from €100,000 to €500,000, often participating in syndicated deals with other specialized investors in the European healthcare ecosystem. Their portfolio reflects a commitment to supporting scientifically rigorous solutions with clear regulatory pathways.

Beyond financial investment, Springboard offers portfolio companies access to an extensive network of clinical partners, research institutions, and pharmaceutical industry connections throughout Germany and broader European markets. This collaborative approach has proven particularly valuable for early-stage companies navigating regulatory approvals, clinical validations, and initial market entry strategies. The angel group actively participates in Berlin's vibrant health innovation ecosystem, frequently collaborating with accelerators, incubators, and research institutions to identify promising technologies at their earliest stages of development.

Springboard's investment committee employs a rigorous evaluation process that assesses not only the scientific merit of proposed technologies but also market viability and scalability potential. Their track record includes several notable success stories, with portfolio companies advancing to secure significant Series A and B funding rounds from institutional investors. The group maintains a particular interest in cross-border innovations that can address healthcare challenges across multiple European markets, reflecting their understanding that successful health technologies must often navigate diverse regulatory environments and healthcare delivery systems to achieve meaningful scale.